Johnson & Johnson (NYSE:JNJ) is Moloney Securities Asset Management LLC’s 3rd Largest Position

27 May 2020, 12:42 by Danessa Lincoln

Moloney Securities Asset Management LLC grew its position in shares of Johnson & Johnson (NYSE:JNJ) by 15.5% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 61,097 shares of the company’s stock after purchasing an additional 8,210 shares during the quarter. Johnson & Johnson makes up about 2.9% of Moloney Securities Asset Management LLC’s portfolio, making the stock its 3rd biggest holding. Moloney Securities Asset Management LLC’s holdings in Johnson & Johnson were worth $8,012,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of the company. Dumont & Blake Investment Advisors LLC boosted its stake in Johnson & Johnson by 0.3% during the 4th quarter. Dumont & Blake Investment Advisors LLC now owns 20,796 shares of the company’s stock worth $3,033,000 after purchasing an additional 71 shares during the last quarter. DE Burlo Group Inc. boosted its stake in Johnson & Johnson by 3.9% during the 4th quarter. DE Burlo Group Inc. now owns 1,871 shares of the company’s stock worth $273,000 after purchasing an additional 71 shares during the last quarter. Modus Advisors LLC boosted its stake in Johnson & Johnson by 2.0% during the 1st quarter. Modus Advisors LLC now owns 3,666 shares of the company’s stock worth $481,000 after purchasing an additional 73 shares during the last quarter. AlphaMark Advisors LLC boosted its stake in Johnson & Johnson by 1.3% during the 4th quarter. AlphaMark Advisors LLC now owns 5,799 shares of the company’s stock worth $846,000 after purchasing an additional 75 shares during the last quarter. Finally, Capital Financial Planning LLC boosted its stake in Johnson & Johnson by 3.6% during the 4th quarter. Capital Financial Planning LLC now owns 2,192 shares of the company’s stock worth $320,000 after purchasing an additional 76 shares during the last quarter. 68.45% of the stock is owned by hedge funds and other institutional investors.

In related news, Director William D. Perez purchased 500 shares of the business’s stock in a transaction dated Friday, March 13th. The stock was acquired at an average price of $127.69 per share, for a total transaction of $63,845.00. Following the completion of the purchase, the director now directly owns 16,030 shares of the company’s stock, valued at $2,046,870.70. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. 0.27% of the stock is owned by corporate insiders.

Shares of JNJ opened at $144.56 on Wednesday. The stock has a 50 day moving average price of $147.76 and a 200 day moving average price of $142.57. The company has a quick ratio of 1.05, a current ratio of 1.31 and a debt-to-equity ratio of 0.41. The company has a market capitalization of $380.36 billion, a price-to-earnings ratio of 19.12, a price-to-earnings-growth ratio of 3.14 and a beta of 0.71. Johnson & Johnson has a 52-week low of $109.16 and a 52-week high of $157.00.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, April 14th. The company reported $2.30 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.03 by $0.27. The business had revenue of $20.69 billion during the quarter, compared to the consensus estimate of $19.48 billion. Johnson & Johnson had a return on equity of 39.71% and a net margin of 24.47%. The company’s revenue was up 3.3% compared to the same quarter last year. During the same period in the prior year, the company earned $2.10 earnings per share. On average, equities analysts anticipate that Johnson & Johnson will post 7.68 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 9th. Stockholders of record on Tuesday, May 26th will be paid a dividend of $1.01 per share. This represents a $4.04 annualized dividend and a dividend yield of 2.79%. The ex-dividend date of this dividend is Friday, May 22nd. This is a boost from Johnson & Johnson’s previous quarterly dividend of $0.95. Johnson & Johnson’s dividend payout ratio is 46.54%.

Several brokerages have issued reports on JNJ. Wells Fargo & Co raised shares of Johnson & Johnson to a “hold” rating in a research note on Wednesday, April 22nd. Stifel Nicolaus lifted their price target on Johnson & Johnson from $140.00 to $155.00 and gave the stock a “hold” rating in a report on Wednesday, April 15th. Barclays lifted their price target on Johnson & Johnson from $173.00 to $182.00 and gave the stock an “overweight” rating in a report on Wednesday, April 29th. Credit Suisse Group reiterated a “buy” rating and set a $161.00 price target on shares of Johnson & Johnson in a report on Tuesday, April 28th. Finally, SVB Leerink reduced their price target on Johnson & Johnson from $172.00 to $160.00 and set an “outperform” rating on the stock in a report on Wednesday, April 8th. Four investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $163.47.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.